{"id":"NCT02347072","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","officialTitle":"A Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-01","primaryCompletion":"2015-08-01","completion":"2016-03-01","firstPosted":"2015-01-27","resultsPosted":"2017-04-19","lastUpdate":"2017-04-19"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"GFF MDI (PT003)","otherNames":["Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)"]},{"type":"DRUG","name":"Placebo MDI","otherNames":["Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"Spiriva® Respimat® (Tiotropium Bromide)","otherNames":[]}],"arms":[{"label":"GFF MDI (PT003)","type":"EXPERIMENTAL"},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR"},{"label":"Spiriva® Respimat® (Tiotropium Bromide)","type":"ACTIVE_COMPARATOR"}],"summary":"Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo.","primaryOutcome":{"measure":"Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24","timeFrame":"Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29","effectByArm":[{"arm":"GFF MDI","deltaMin":0.192,"sd":null},{"arm":"Spiriva Respimat","deltaMin":0.112,"sd":null},{"arm":"Placebo","deltaMin":-0.072,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28821260"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":75},"commonTop":["Headache","Cough","Constipation","Vomiting","Tremor"]}}